Telix Pharmaceuticals is trading 6.7% down at $11.03 after falling from its August 14, 2026 close of $11.82, with no clear company-specific catalyst identified for the pre-market decline.
- Major U.S. futures are modestly positive, making broad market weakness an unlikely explanation.
- First-half 2026 results are scheduled for August 20, 2026; no earnings announcement or fresh material event was found for August 17.